Fujian Cosunter Pharmaceutical Co Ltd Tangible Net Worth Ratio
Fujian Cosunter Pharmaceutical Co Ltd tangible net worth ratio. Fujian Cosunter Pharmaceutical Co Ltd (300436) has a Tangible Net Worth Ratio of 26.6% as of June 2026. This metric is calculated by deducting intangible assets (CN¥200.06 Million) from net assets (CN¥272.54 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check 300436 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Fujian Cosunter Pharmaceutical Co Ltd (2011–2025)
Tangible net worth ratio of Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025. This chart shows how Fujian Cosunter Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 26.6%, reflecting net assets of CN¥272.54 Million with intangible assets of CN¥200.06 Million CNY. See Fujian Cosunter Pharmaceutical Co Ltd (300436) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Fujian Cosunter Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2011–2025)
Fujian Cosunter Pharmaceutical Co Ltd tangible net worth ratio by year from 2011 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 300436 market cap.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 45.4% | CN¥346.30 Million | CN¥188.97 Million | CN¥1.40 Billion | ▲ +10.3 pp |
| 2024 | 35.1% | CN¥396.78 Million | CN¥257.49 Million | CN¥1.44 Billion | ▼ -12.7 pp |
| 2023 | 47.8% | CN¥569.24 Million | CN¥297.08 Million | CN¥1.61 Billion | ▼ -39.4 pp |
| 2022 | 87.2% | CN¥955.62 Million | CN¥122.28 Million | CN¥1.49 Billion | ▲ +0.9 pp |
| 2021 | 86.3% | CN¥1.05 Billion | CN¥144.21 Million | CN¥1.45 Billion | ▲ +12.0 pp |
| 2020 | 74.2% | CN¥581.99 Million | CN¥149.98 Million | CN¥1.01 Billion | ▲ +6.0 pp |
| 2019 | 68.2% | CN¥573.74 Million | CN¥182.19 Million | CN¥896.25 Million | ▼ -6.8 pp |
| 2018 | 75.1% | CN¥562.35 Million | CN¥140.14 Million | CN¥854.68 Million | ▼ -13.8 pp |
| 2017 | 88.9% | CN¥552.05 Million | CN¥61.52 Million | CN¥736.47 Million | ▼ -2.4 pp |
| 2016 | 91.2% | CN¥552.36 Million | CN¥48.57 Million | CN¥700.67 Million | ▼ -0.6 pp |
| 2015 | 91.8% | CN¥519.20 Million | CN¥42.36 Million | CN¥600.70 Million | ▲ +7.2 pp |
| 2014 | 84.7% | CN¥156.87 Million | CN¥24.04 Million | CN¥224.11 Million | ▲ +0.2 pp |
| 2013 | 84.5% | CN¥143.10 Million | CN¥22.20 Million | CN¥197.53 Million | ▲ +0.9 pp |
| 2012 | 83.6% | CN¥108.59 Million | CN¥17.84 Million | CN¥149.41 Million | ▼ -0.9 pp |
| 2011 | 84.4% | CN¥65.43 Million | CN¥10.18 Million | CN¥109.29 Million | — |